Our news

08.07.2019

NeoPhore appoints Dr Matthew Baker as VP Immunology

08 July 2019, Cambridge, UK – NeoPhore Limited, a small molecule cancer immuno-oncology company, today announces the appointment of Dr Matthew Baker a…

17.05.2019

Neophore's SAB member publishes article on JCO Precision Oncology

Dr. Luis Diaz, Neophore’s Scientific Advisory Member and Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Hospital has r…

20.03.2019

NeoPhore appoints Dr John Haurum as Non-Executive Director

Former F-star CEO joins the Board of Directors. NeoPhore Limited, a cancer immuno-oncology company, today announces the appointment of Dr John…

27.04.2018

NeoPhore and PhoreMost Receive Innovate UK Funding to Support Development of a Novel Small-Molecule Cancer Immunotherapy Programme

Grant award funds expanded operations and recognizes innovative drug discovery programme 27th April 2018, Cambridge, UK – NeoPhore Limited, a cancer i…

Other news

08.02.2018

NeoPhore Enters Immuno-Oncology Fray With DNA-Repair Technology

Scrip Emerging company profile: UK-based NeoPhore, founded in 2017, is developing novel cancer therapies based on DNA-repair technology. The company…

06.12.2017

UK’s NeoPhore pioneers new approach to cancer immunotherapy

Pharmaphorum: Newly launched UK biotech is looking to develop a new approach to immunotherapy, based around a seemingly paradoxical idea that…